GUCD1

Across TCGA pan-cancer cohorts, GUCD1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated GUCD1 data layer compared with 24 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher GUCD1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated GUCD1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LUAD, and LSCC are the cancer types where GUCD1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.698	0.174	.017	11	view →
LUAD	OS	Median	All	0.361	0.868	.045	2	view →
LSCC	DFS	Median	All	1.000	0.958	.046	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

GUCD1–PDAC (DFS)

Open the PDAC breakdown →